This newer mode of administration for immunotherapy comes with benefits and risks. It is important for a person to work with a doctor when making treatment decisions for upper gastrointestinal (GI) ...

A person receives subcutaneous immunotherapy as an injection under the skin. This treatment method has shown similar effectiveness to intravenous (IV) infusions that healthcare professionals often use ...

The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way anti-cancer immunotherapy is administered from intravenous administration to ...

Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...

Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. Seventy-three patients were given CdA as a subcutaneous injection once daily for 7 days. Complete remission (CR) ...

A new auto-injecting pill might soon become a replacement for subcutaneous injection treatments. The idea for this so-called robotic pill came out of a research project around eight years ago from ...

The U.S. Food and Drug Administration (FDA) has approved a new way to give pembrolizumab (brand name: Keytruda), one of the most widely used immunotherapy treatments for cancer. For the first time, ...

Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myelomaApproval based on multiple studies, including the ...

The phase 3 IRAKLIA trial found that subcutaneous isatuximab delivered via an on-body system was as effective and safe as intravenous (IV) administration in relapsed/refractory multiple myeloma, ...

Marketing Approval Expands Treatment to Include Nearly 11 Million Patients Who Experience Opioid-Induced Constipation While Taking Opioids for Chronic Non-Cancer Pain RALEIGH, N.C. & TARRYTOWN, N.Y.-- ...

Sanofi's subcutaneous formulation of multiple myeloma drug Sarclisa has been approved in the UK, which will be the first market for the on-body injector (OBI) version of the drug.